CD8A and neoplasm: The TME suppresses the levels of LDLR in CD8+ T cells and their TCR signaling through tumor cell-derived PCSK9. Genetic deletion or pharmacological inhibition of PCSK9 in tumor cells appears to improve the antitumor response of CD8+ T cells by alleviating their suppression.